Related Experiment Videos
A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children
Insights
Both patching and atropine effectively treat moderate amblyopia in young children. These treatments for amblyopia (lazy eye) show similar visual acuity improvements after six months.
Area of Science:
- Ophthalmology
- Pediatric Medicine
- Clinical Trials
Background:
- Amblyopia, or lazy eye, is a common cause of reduced vision in children.
- Early intervention is crucial for effective amblyopia treatment.
Purpose of the Study:
- To compare the efficacy of patching versus atropine for treating moderate amblyopia in children under 7 years old.
Main Methods:
- A randomized clinical trial involving 419 children younger than 7 years with moderate amblyopia.
- Participants were assigned to receive either patching or atropine treatment.
- Visual acuity was measured in the amblyopic and sound eyes after 6 months.
Main Results:
- Both patching and atropine groups showed significant visual acuity improvement.
- The difference in visual acuity between the groups after 6 months was small and not clinically significant.
- Both treatments were well-tolerated, with atropine showing slightly higher parental acceptability.
Conclusions:
- Patching and atropine are both effective and appropriate initial treatments for moderate amblyopia in children aged 3 to under 7 years.
- The magnitude of visual improvement is similar between the two treatment modalities.
Objective:
To compare patching and atropine as treatments for moderate amblyopia in children younger than 7 years.
Methods:
In a randomized clinical trial, 419 children younger than 7 years with amblyopia and visual acuity in the range of 20/40 to 20/100 were assigned to receive either patching or atropine at 47 clinical sites.
Main Outcome Measure:
Visual acuity in the amblyopic eye and sound eye after 6 months.
Results:
Visual acuity in the amblyopic eye improved in both groups (improvement from baseline to 6 months was 3.16 lines in the patching group and 2.84 lines in the atropine group). Improvement was initially faster in the patching group, but after 6 months, the difference in visual acuity between treatment groups was small and clinically inconsequential (mean difference at 6 months, 0.034 logMAR units; 95% confidence interval, 0.005-0.064 logMAR units). The 6-month acuity was 20/30 or better in the amblyopic eye and/or improved from baseline by 3 or more lines in 79% of the patching group and 74% of the atropine group. Both treatments were well tolerated, although atropine had a slightly higher degree of acceptability on a parental questionnaire. More patients in the atropine group than in the patching group had reduced acuity in the sound eye at 6 months, but this did not persist with further follow-up.
Conclusion:
Atropine and patching produce improvement of similar magnitude, and both are appropriate modalities for the initial treatment of moderate amblyopia in children aged 3 to less than 7 years.